Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase II drugs for Pleomorphic Liposarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Polzastobart LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Polzastobart overview

Polzastobart (JTX-8064) is under development for the treatment of cold tumor including naïve platinum resistant ovarian cancer, head and neck squamous cell carcinoma (HNSCC), extrahepatic bile duct cancer, gallbladder cancer, undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS), non-small cell lung cancer (NSCLC), renal cell carcinoma (ccRCC), triple negative breast cancer (TNBC), cutaneous squamous cell carcinoma (cSCC). It acts by targeting LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2). The drug candidate is developed based on translational science platform. It is administered through intravenous route.

Concentra Biosciences overview

Concentra Biosciences is a bioscience company that develops novel immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California, the US.

For a complete picture of Polzastobart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.